Numis Securities Ltd reissued their buy rating on shares of Allergy Therapeutics plc (LON:AGY) in a report released on Tuesday morning, Marketbeat Ratings reports. Numis Securities Ltd currently has a GBX 45 ($0.59) target price on the stock.

Other equities research analysts have also issued reports about the stock. FinnCap boosted their target price on shares of Allergy Therapeutics plc from GBX 43 ($0.56) to GBX 46 ($0.60) and gave the stock a buy rating in a report on Tuesday. Panmure Gordon reissued a buy rating and set a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a report on Thursday, April 20th. Finally, Stifel Nicolaus reissued a buy rating and set a GBX 60 ($0.78) target price on shares of Allergy Therapeutics plc in a report on Tuesday, April 4th.

Allergy Therapeutics plc (AGY) opened at 30.125 on Tuesday. The firm has a 50-day moving average of GBX 26.26 and a 200-day moving average of GBX 25.56. Allergy Therapeutics plc has a 52 week low of GBX 17.25 and a 52 week high of GBX 31.00. The company’s market capitalization is GBX 178.77 million.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/07/19/allergy-therapeutics-plcs-agy-buy-rating-reaffirmed-at-numis-securities-ltd.html.

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.